Product: Alcon’s AcrySof IQ PanOptix Trifocal Intraocular Lens (IOL) 
Top Line: PanOptix is the first and only trifocal lens for U.S. patients undergoing cataract surgery.
Close Up: Alcon announced Tuesday that the FDA has approved the new PanOptix Trifocal lens, which is clinically shown to deliver an exceptional combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery. PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries, according to Alcon. The new lens is designed for today’s active lifestyles, from viewing mobile devices and computer screens to high-quality distance vision in a range of lighting conditions, according to Alcon’s announcement. It uses Enlighten Optical Technology, a proprietary design that optimizes intermediate vision without compromising near and distance vision. The lens will be available in spherical and toric designs, and is built on Alcon’s proven AcrySof IQ IOL platform, which has been implanted in more than 120 million eyes globally. More than ninety-nine percent of PanOptix patients in the FDA clinical study said they would choose the same lens again, according to Alcon. U.S. surgeon training and patient awareness efforts will begin immediately with a ramp up into early 2020. Alcon expects to make inventory of PanOptix and PanOptix Toric IOLs available through the rest of 2019 into early 2020. As part of its patient education efforts, the company will soon launch a dedicated PanOptix website and multimedia awareness campaign. A similar effort is planned for eye care professionals with special launch activities slated for the annual meeting of the American Academy of Ophthalmology in October.
Vital Stats: The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the U.S. With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision, according to Alcon. The results also showed high patient satisfaction with more than ninety-nine percent of PanOptix patients saying they would choose the same lens again.